The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $432.72

Today's change-0.73 -0.17%
Updated September 22 4:00 PM EDT. Delayed by at least 15 minutes.
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $432.72

Today's change-0.73 -0.17%
Updated September 22 4:00 PM EDT. Delayed by at least 15 minutes.

Regeneron Pharmaceuticals Inc down (U.S.)$0.73

Regeneron Pharmaceuticals Inc closed lower Friday, dropping (U.S.)$0.73 or 0.17% to (U.S.)$432.72. Over the last five days, shares are unchanged, but have gained 17.88% over the last year to date. This security has underperformed the S&P 500 by 8.87% during the last year.

Key company metrics

  • Open(U.S.) $431.12
  • Previous close(U.S.) $433.45
  • High(U.S.) $433.77
  • Low(U.S.) $427.04
  • Bid / Ask(U.S.) $430.01 / (U.S.) $469.98
  • YTD % change+17.88%
  • Volume626,312
  • Average volume (10-day)902,487
  • Average volume (1-month)722,130
  • Average volume (3-month)849,493
  • 52-week range(U.S.) $325.35 to (U.S.) $543.55
  • Beta1.64
  • Trailing P/E43.44×
  • P/E 1 year forward29.05×
  • Forward PEG1.61×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $9.96
Updated September 22 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology

Latest Company News

View more News
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue1,4701,3191,2271,220
Total other revenue--------
Total revenue1,4701,3191,2271,220
Gross profit1,3671,2351,1521,176
Total cost of revenue103847544
Total operating expense920888880857
Selling / general / administrative307297326270
Research & development510507479543
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income550431347363
Interest income (expense), net non-operating-5-8----
Gain (loss) on sale of assets--------
Other--------
Income before tax526432342366
Income after tax388249253265
Income tax, total13818388101
Net income388249253265
Total adjustments to net income--------
Net income before extra. items388249253265
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items388249253265
Inc. avail. to common incl. extra. items388249253265
Diluted net income388249253265
Dilution adjustment0--00
Diluted weighted average shares116115116116
Diluted EPS excluding extraordinary itemsvalue per share3.342.162.192.27
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share3.342.162.192.27